Skin Burn – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Skin Burn Emerging Therapy and TPP Insights

Thelansis’s “Skin Burn Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Skin Burn Overview

Burn pain is a complex and often severe pain condition associated with burn wounds, characterized by acute nociceptive signaling from damaged skin and deeper tissues, with inflammatory mediators amplifying peripheral and central sensitization. Pain intensity varies with burn depth, extent, anatomical location, wound healing, and procedural interventions such as debridement, dressing changes, and grafting. Patients may experience continuous background pain alongside episodic procedural and breakthrough pain, while neuropathic features can emerge during healing and persist in some individuals. Effective management commonly requires multimodal analgesia combining systemic and regional approaches with appropriate wound care and non-pharmacological interventions. Despite advances in pain management, achieving sustained analgesia without excessive sedation, respiratory depression, opioid-related adverse effects, or other treatment limitations remains challenging. This unmet need is driving interest in opioid-sparing strategies, targeted analgesics, regional therapies, and novel agents designed to modulate peripheral nociception, neuroinflammation, and pain sensitization while supporting functional recovery.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)